Day One’s Powerful $285 Million Acquisition Sparks Hope for Rare Cancer Patients

Day One Biopharmaceuticals will acquire Mersana Therapeutics in a deal worth up to $285 million, expanding its oncology portfolio with Emi-Le, a promising therapy for rare, aggressive adenoid cystic carcinoma (ACC).




